Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Editorial Board501
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer261
Editorial Board206
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor197
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea179
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor175
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma169
Modulating undruggable targets to overcome cancer therapy resistance152
Erratum to “A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24- enriched breast cancer stem-like cells” [Drug Resist. Updates 66 (2023) 100903]148
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome131
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer127
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma127
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance122
Unraveling the secrets: Evolution of resistance mediated by membrane proteins120
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects119
Editorial Board118
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions117
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine99
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis99
Evolution of RND efflux pumps in the development of a successful pathogen98
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer90
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies85
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China80
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance80
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges78
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae76
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs74
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells72
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC72
Peptide nanonet trapping suppresses bacterial motility and delays antibiotic resistance emergence69
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond67
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma61
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer59
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs59
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation59
Editorial Board58
Targeting anoikis resistance as a strategy for cancer therapy58
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer57
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress57
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights56
The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: Implications for therapy resistance and tumor recurrence56
Research progress on gene mutations and drug resistance in leukemia54
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds53
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity52
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica52
Myeloid Immune Checkpoint Blockade Overcomes Antibiotic Resistance in Bone Infection by Enhancing Efferocytosis and Suppressing MSC PANoptosis50
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma49
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers49
Current therapy and drug resistance in metastatic castration-resistant prostate cancer49
0.056379079818726